Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Queen Mary Hospital, Hong Kong, China.

Survival: monthsCountry:China
Toxiciy Grade:4City/State/Province:Hong Kong
Treatments:Biologic therapyHospital:Queen Mary Hospital
Drugs:Journal:Link
Date:Jan 2009

Description:

Patients:
This Phase 2 study involved 51 patients with hepatocellular carcinoma. Of these, 88% were male and the median age was 56 years with a range of 28-79.

Treatment:
Patients were administered the biological agent sorafenib. Sorafenib is a small molecular inhibitor of several Tyrosine protein kinases.

Toxicities:
The maximum level of toxicity reported was grade 4 (anemia and liver biochemistry effects). Other side effects included thrombocytopenia, diarrhea, and hand-foot skin reaction (redness of hands and feet, also known as hand-foot syndrome).

Results:
The median overall survival was 5 months with a range of 3-17 months. Overall median progression-free survival was 3 months with a range of 3-17 months.

Correspondence: Dr. Ronnie T. Poon; email: [email protected]



Back